Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Forest Laboratories: Finding Ways to Bring Drugs to Market — Fast
- Pfizer may be big, but Forest Laboratories is nimble. The smaller company competes by ushering drugs through FDA red tape in record time. Giant: Pfizer Shadow Success: Forest Laboratories, Inc. Pfizer market cap: $96.56 billion;...
- Articles 2009-06-10
- In the Shadow of Giants
- Sure, only one company can be No. 1. But so what? Smaller firms have plenty of advantages — and they often outperform industry leaders. Here are four who are thriving in the shadows.Bigger is almost always better when it comes to business — at least that's the common belief. Big...
- Articles 2009-06-10
Additional Resources
- Caraco Pharmaceutical Laboratories, Ltd. Enters Into Asset Purchase Agreement with Forest Laboratories, Inc. to Settle Lexapro® ANDA Patent Litigation
- DETROIT, July 10 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD) announced that, as part of the settlement of the legal proceedings related to LexaproR escitalopram oxalate tablets, it entered into an Asset Purchase Agreement with Forest Laboratories, Inc. ("Forest") to acquire several products from Forest's...
- Research articles 2009-07-10
- Forest Laboratories and H. Lundbeck A/S Enter Into Settlement Agreement With Sun and Caraco Related to LEXAPRO® Patent Litigation
- NEW YORK, July 10, 2009 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. and its wholly-owned subsidiary, Forest Laboratories Holdings, Ltd. (collectively, "Forest"), and H. Lundbeck A/S ("Lundbeck") announced today that they have entered into a settlement agreement with Sun Pharmaceutical Industries Ltd. ("Sun Pharma", a reference that...
- Research articles 2009-07-10
- Forest Laboratories Inc. (Active Pharmaceutical Ingredient Watch).(Alzheimer's disease drug application with FDA voluntarily withdrawn after Phase III trial)(Government Activity)(Product Development)(Brief Article)
- FOREST Laboratories Inc. has voluntarily withdrawn its new drug application NDA with the Food and Drug Administra-tion FDA to market memantine for moderate-to-severe Alzheimer's disease. Forest expects a refiling and submission of new study dat FOREST Laboratories Inc. has voluntarily withdrawn its new drug...
- Research articles 2002-09-30
- Forest Laboratories, Inc.(theInvestmentSection)
- Profile: Forest Laboratories, Inc. (NYSE: FRX) develops, manufactures, and markets prescription pharmaceutical products in the U.S. Forest has successful branded pharmaceutical products; and strong revenue and profit growth. Profile: Forest Laboratories, Inc. (NYSE: FRX) develops, manufactures, and markets prescription pharmaceutical products in...
- Research articles 2005-09-01
- Forest Laboratories Inc. (Active Pharmaceutical Ingredient Watch).(Brief Article)
- FOREST Laboratories Inc. reported a 45 percent increase in earnings per share BPS to 48 cents in the first quarter of fiscal 2004. Net sales rose 5 percent to ... FOREST Laboratories Inc. reported a 45 percent increase in earnings per share BPS to...
- Research articles 2003-07-21
- Forest Laboratories Inc. (Active Pharmaceutical Ingredient Watch).(Brief Article)
- FOREST Laboratories Inc.'s licensor, Lipha SA, a subsidiary of Merck KGaA, has been granted priority review with FDA for its new drug application ... FOREST Laboratories Inc.'s licensor, Lipha SA, a subsidiary of Merck KGaA, has been granted priority review with FDA for its...
- Research articles 2002-03-04
- European drug strategy makes Forest stand out; Revenue triples in 5 years; does firm need to turn over leaf to stay green?(News)(Forest Laboratories Inc.)
- Byline: samantha marshall After five years of dizzying gains, Forest Laboratories Inc. has become one of the few stars in an industry better known for incremental growth. Propelled by its ability to rapidly develop European drugs for the U.S. m ...
- Research articles 2003-12-08
- Forest Laboratories Inc. (Active Pharmaceutical Ingredient Watch).(FDA advisory panel voted positively on the efficacy of acamprosate)(Brief Article)
- FOREST Laboratories Inc. reports a FDA advisory panel voted positively on the efficacy of acamprosate, a drug to help maintain abstinence in alcohol-dependent patients, when used in conjunction with counseling. Acamprosate ... FOREST Laboratories Inc. reports a FDA advisory panel voted positively on...
- Research articles 2002-05-20
- Forest Laboratories Inc. (Active Pharmaceutical Ingredient Watch).(fiscal 2003 third quarter results)(Brief Article)
- FOREST Laboratories Inc. preannounced its fiscal 2003 third quarter results. The company projects that earnings per share EPS will ... FOREST Laboratories Inc. preannounced its fiscal 2003 third quarter results. The company projects that earnings per share EPS will exceed the current consensus estimate...
- Research articles 2003-01-13
- NERAMEXANE Forest Laboratories Inc.(Brief Article)
- NERAMEXANE Forest Laboratories Inc. will develop and market neramexane, a patented novel NMDA receptor antagonist developed by Merz and Co. of ... NERAMEXANE Forest Laboratories Inc. will develop and market neramexane, a patented novel NMDA receptor antagonist developed by Merz and Co. of...
- Research articles 2001-07-09
- Forest Laboratories Inc. (Active Pharmaceutical Ingredient Watch).(stock price, net income data)(Brief Article)
- FOREST Laboratories Inc.'s stock fell 6 percent to $49.40 last week on fiscal fourth quarter 2003 earnings. Net income, while up 87 percent to $181 million, or 48 cents per share, fell short of Wall Street consensus by 1 cent, in part due to higher ...
- Research articles 2003-04-28
- Forest Laboratories Inc. (Active Pharmaceutical Ingredient Watch).(financial data)(Brief Article)
- FOREST LABORATORIES Inc. posted fiscal second quarter 2003 net income up 79 percent to $143 million, or 77 ... FOREST LABORATORIES Inc. posted fiscal second quarter 2003 net income up 79 percent to $143 million, or 77 cents per share, 3 cents ahead of...
- Research articles 2002-10-21
- Q3 2006 Forest Laboratories, Inc. Earnings Conference Call - Research and Markets Offers a Brief of Forest Laboratories, Inc. Conference Call
- BOSTON -- The Forest Laboratories, Inc. (NYSE:FRX) Corporate Conference Call took place on 17-Jan-06 10:00am ET. Management discussed 3Q06 results, reporting fully-diluted EPS of $0.57 on total revenues of $758m. Guidance was for FY06 revenue and EPS of approx. $3b and approx. $2.30 respectively.
- Research articles 2006-01-17
- EquityOutlook.Com Announces Stock Evaluation Ratings for Au Optronics, Forest Laboratories, Kinross Gold Corporation, Cerner, and Goldcorp.
- M2 PRESSWIRE-10 February 2004-EquityOutlook.Com: EquityOutlook.Com Announces Stock Evaluation Ratings for Au Optronics, Forest Laboratories, Kinross Gold Corporation, Cerner, and Goldcorp.C1994-2004 M2 COMMUNICATIONS LTD RDATE:02102004 SHREVEPORT, La. - EquityOutlook.Com makes these short-term stock recommendations: AU Optronics Corporation (NYSE:AUO)...
- Research articles 2004-02-10
- New ratings on Dupont E I Nemours & Co, Corvis Corporationn, Forest Laboratories Inc, Conoco Inc, Barrick Gold Corp.
- M2 PRESSWIRE-17 January 2002-StockPickReport.Com: New ratings on Dupont E I Nemours & Co, Corvis Corporationn, Forest Laboratories Inc, Conoco Inc, Barrick Gold Corp C1994-2002 M2 COMMUNICATIONS LTD RDATE:17012002 StockPickReport.Com ( http://www.stockpickreport.com ) Rates the following stocks for the...
- Research articles 2002-01-17
- Forest Laboratories Signs Grants Manager Agreement With Fast Track Systems
- Fast Track Systems, Inc., a leading provider of clinical trial software designed to reduce the cost and improve productivity within clinical trial operations, today announced that Forest Laboratories, Inc. (NYSE: FRX) has selected TrialSpaceTM Grants Manager® to assist in its global clinical trial costing activities. Using Grants Manager, Forest...
- Research articles 2006-04-19
- Zacks.com Announces That Ian Wyatt Highlights the Following Stocks: Forest Laboratories, Merck, Pfizer, Bentley Pharmaceuticals and Impax Laboratories
- CHICAGO -- Ian Wyatt profiles one drug company avoiding the contagion of its peers and offering a unique buying opportunity. Read about Forest Laboratories (NYSE:FRX), Merck & Co. (NYSE:MRK), Pfizer (NYSE:PFE), Bentley Pharmaceuticals Inc. (AMEX:BNT), and Impax Laboratories (NASDAQ:IPXL). Ian Wyatt is editor of the Growth Report newsletter. Click here...
- Research articles 2004-10-18
- Schaeffer's S&P 500 Index Hot Stocks Features Apple Computers, Campbell Soup, UnumProvident, Forest Laboratories, and Mylan Laboratories
- CINCINNATI -- Among the stocks featured in the November 22 edition of Schaeffer's S&P 500 Index Hot Stocks are Apple Computers (NASDAQ:AAPL), Campbell Soup (NYSE:CPB), UnumProvident (NYSE:UNM), Forest Laboratories (NYSE:FRX), and Mylan Laboratories (NYSE:MYL). Schaeffer's S&P 500 Index Hot Stocks is just one of the many free market commentaries written...
- Research articles 2004-11-22
- << Previous
- page 1 of 1
- Next >>
